ObjectiveThis article aims to summarize the historical evolution of thyroid cancer molecular classification and explore the establishment of a precise classification system based on molecular characteristics and its impact on clinical applications. MethodsA literature review was conducted to analyze and organize the recent influences of molecular classification of thyroid cancer on clinical diagnosis and treatment. ResultsIn recent years, the classification of thyroid cancer has introduced molecular features such as BRAF and RAS mutations, highlighting the close association between these molecular characteristics and prognosis. For example, the BRAF V600E mutation is associated with high aggressiveness in papillary thyroid cancer, while RAS mutations suggest malignant potential in follicular tumors. With the advancement of multi-omics research, classification strategies based on multi-omics have shown significant value in the diagnosis, monitoring, treatment, and prognostic assessment of thyroid cancer. Although multi-omics integration has significantly improved the accuracy of prognostic assessments in thyroid cancer, there are still limitations, including imprecise detection of tumor heterogeneity and insufficient sensitivity and specificity of molecular biomarker detection.ConclusionsThe classification of thyroid cancer is developing towards the integration of molecular features to achieve more precise diagnosis and treatment. To accomplish this goal, it is necessary to overcome the challenges of tumor heterogeneity and the limitations of detection technologies in the future, and to promote the practical application of molecular classification in clinical settings.
